NDASUBCUTANEOUSINJECTABLE
Approved
Apr 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
45
Mechanism of Action
Glucagon-like Peptide-1 (GLP-1) Agonists
Pharmacologic Class:
GLP-1 Receptor Agonist
Indications (1)
Clinical Trials (5)
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
Started Sep 2024
24,000 enrolled
Pancreatic Cancer
Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus
Started Jun 2020
0Type 2 Diabetes
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
Started Feb 2018
13 enrolled
ObesityDiabetes Mellitus, Type 2
Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM
Started Dec 2017
90 enrolled
Diabetes Mellitus, Type 2
DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2
Started Sep 2017
65 enrolled
Type 2 Diabetes MellitusObesity